Latest Content

Imneskibart showed promising outcomes and tolerability in patients who had previously received immune checkpoint inhibition for either melanoma or lung adenocarcinoma.

Renuka Iyer, MD, explains how NCCN is digitizing its guidelines with structured data to support AI tools, prior authorization, and point-of-care access.

The FDA accepted an sNDA for gedatolisib in PIK3CA-mutant HR+/HER2– advanced breast cancer based on the phase 3 VIKTORIA-1 trial, with a PDUFA date of June 25, 2027.

The FDA grants orphan drug designation to TRX-E-002-1, an investigational small-molecule benzopyran, for the treatment of acute myeloid leukemia (AML).

In KEYNOTE-867, adding pembrolizumab to radiotherapy did not extend event-free survival in inoperable early-stage NSCLC and raised toxicity; the phase 3 trial was stopped for futility in 2024.

Arvind Dasari, MD, MS, reviews key advances in neuroendocrine tumors, including new PRRT options, alpha emitters, cabozantinib, and clinical trials.

Arvind N. Dasari, MD, MS, reviews a year in neuroendocrine tumors marked by expanding radioligand options, improved classification, and disappointing combination therapies.

Older age, kidney disease, and prior irradiation were linked to elevated myeloid neoplasm risk after lutetium Lu 177 dotatate in a real-world NET analysis.

Aman Chauhan, MD, discusses combining intratumoral Seneca Valley virus (SVV-001) with ipilimumab and nivolumab in neuroendocrine cancer.

Nikolaos Trikalinos, MD, reviews CABINET data showing cabozantinib improved PFS in functional and nonfunctional NETs without added grade 3 toxicity.

Liver transplant led to durable survival in unresectable NET liver metastases; tumor burden predicted outcomes, and recurrence was common but treatable.

Mark A. Lewis, MD, explains how oral cabozantinib reduces time toxicity for patients with previously treated, well-differentiated neuroendocrine tumors.

Erica S. Alexander, MD, highlights endovascular approaches to venous occlusion, including stenting and thrombolysis, for select patients with NETs.

Amr Mohamed, MD, reviews zocilurtatug pelitecan phase 1/2 data in platinum-refractory extrapulmonary neuroendocrine carcinoma.

In a phase 1 trial, a single intratumoral injection of oncolytic virus SVV-001 with ipilimumab and nivolumab was safe in high-grade neuroendocrine cancers.

Halfdan Sørbye, MD, PhD, discusses why accurately distinguishing NET G3 from NEC is critical, as the wrong first-line therapy can shorten survival.

Zocilurtatug pelitecan, a DLL3-targeted ADC, showed meaningful responses and managea-ble safety in previously treated epNEC, regardless of DLL3 expression.

Oncologists discuss LITESPARK-011 findings and the potential role of belzutifan plus lenvatinib in second-line advanced renal cell carcinoma treatment and sequencing.

In DAREON-7, first-line obrixtamig plus chemo yielded responses across DLL3 expression levels in epNEC, with the most durable in DLL3-high tumors.

In the CABINET trial, cabozantinib extended PFS vs placebo in advanced NETs regardless of hormone functional status, with similar safety across subgroups.

Jennifer R. Eads, MD, discussed radioligand therapy in younger and older patients with NETs, highlighting safety data and gaps in clinical evidence.

The FDA assigned an April 9, 2027, PDUFA date to rivoceranib plus camrelizumab for first-line treatment of unresectable or metastatic hepatocellular carcinoma.

The Community Oncology Alliance said CMS’s final 2027 outpatient rule pays 340B hospitals ASP minus 28% for drugs, but physician payment cuts still threaten practices.

PRRT retreatment achieved high disease control in NETs, and longer benefit from first PRRT was tied to longer progression-free survival after retreatment.

The investigational alpha emitter 212Pb-VMT-α-NET yielded encouraging response rates in PRRT-naive SSTR2+ NETs.

Erik S. Mittra, MD, PhD, highlighted how new PRRT trials may reshape neuroendocrine tumor care, from retreatment and dosimetry to alpha-emitting therapies.

Chrisann Kyi, MD, discusses the 79.3% response rate with sofetabart mipitecan plus bevacizumab in platinum-sensitive ovarian cancer and phase 3 plans.

The FDA has granted accelerated approval to amivantamab and hyaluronidase for advanced HNSCC based on the OrigAMI-4 trial.

During a live event, Wade T. Iams, MD, discussed the issues facing oncologists selecting treatment for patients with extensive-stage small cell lung cancer.

The planned study will evaluate the investigational PET imaging agent in approximately 280 patients with indeterminate brain metastases following radiotherapy.

In OptimUM-01, first-line darovasertib plus crizotinib produced a 34.1% ORR and 21.1-month median OS in metastatic uveal melanoma, with activity across HLA subgroups.